Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

التفاصيل البيبلوغرافية
العنوان: Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
المؤلفون: Naresh Bumma, Joshua Richter, Jason Brayer, Jeffrey A. Zonder, Madhav Dhodapkar, Mansi R. Shah, James E. Hoffman, Raya Mawad, Joseph J. Maly, Suzanne Lentzsch, Attaya Suvannasankha, Pourab Roy, Jyotirmoy Dey, Dhruti Chokshi, Anita Boyapati, Jenn Visich, Yariv Houvras, Karen Rodriguez Lorenc, Glenn S. Kroog, Sundar Jagannath
المصدر: Blood. 140:10140-10141
بيانات النشر: American Society of Hematology, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry
تدمد: 1528-0020
0006-4971
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::45b0ed2730650e2f9341b7e5ed3ea2ab
https://doi.org/10.1182/blood-2022-159969
رقم الأكسشن: edsair.doi...........45b0ed2730650e2f9341b7e5ed3ea2ab
قاعدة البيانات: OpenAIRE